Literature DB >> 19668643

The use of botulinum toxin in paediatric hypertonia.

Darcy Fehlings1.   

Abstract

Botulinum toxin has become an important component of standard practice in the management of children with hypertonia (spasticity or dystonia). Following intramuscular injection, the neurotoxin causes a reversible neuromuscular blockade, creating both muscle weakness and a reduction in tone. Frequent goals of botulinum toxin injection include improving motor function, promoting longitudinal muscle growth and decreasing painful muscle spasms. The neuromuscular blockade lasts for three to six months on average. The clinical effect may last longer and the safety profile is excellent. Strong evidence, including randomized trials, exists for the efficacy of botulinum toxin in the management of lower and upper extremity tone in children. Common clinical indications include spastic equinus (toe walking), hip subluxation, upper extremity spasticity associated with hemiplegia or quadriplegia, and multilevel leg muscle injections in children with spastic diplegia.

Entities:  

Keywords:  Botulinum toxin; Cerebral palsy; Dystonia; Hypertonia; Spasticity

Year:  2005        PMID: 19668643      PMCID: PMC2722557     

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  16 in total

Review 1.  Therapeutic uses of botulinum toxin.

Authors:  J Jankovic; M F Brin
Journal:  N Engl J Med       Date:  1991-04-25       Impact factor: 91.245

Review 2.  Properties and use of botulinum toxin and other microbial neurotoxins in medicine.

Authors:  E J Schantz; E A Johnson
Journal:  Microbiol Rev       Date:  1992-03

Review 3.  Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment.

Authors:  B S Russman; A Tilton; M E Gormley
Journal:  Muscle Nerve Suppl       Date:  1997

4.  Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial.

Authors:  I S Corry; A P Cosgrove; C M Duffy; S McNeill; T C Taylor; H K Graham
Journal:  J Pediatr Orthop       Date:  1998 May-Jun       Impact factor: 2.324

5.  Botulinum toxin A in the hemiplegic upper limb: a double-blind trial.

Authors:  I S Corry; A P Cosgrove; E G Walsh; D McClean; H K Graham
Journal:  Dev Med Child Neurol       Date:  1997-03       Impact factor: 5.449

6.  Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy.

Authors:  P J Flett; L M Stern; H Waddy; T M Connell; J D Seeger; S K Gibson
Journal:  J Paediatr Child Health       Date:  1999-02       Impact factor: 1.954

7.  Botulinum toxin type A injections in the spastic upper extremity of children with hemiplegia: child characteristics that predict a positive outcome.

Authors:  D Fehlings; M Rang; J Glazier; C Steele
Journal:  Eur J Neurol       Date:  2001-11       Impact factor: 6.089

Review 8.  Outcome measurement of effectiveness of botulinum toxin type A in children with cerebral palsy: an ICIDH-2 approach.

Authors:  R N Boyd; R M Hays
Journal:  Eur J Neurol       Date:  2001-11       Impact factor: 6.089

9.  Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial.

Authors:  S Barwood; C Baillieu; R Boyd; K Brereton; J Low; G Nattrass; H K Graham
Journal:  Dev Med Child Neurol       Date:  2000-02       Impact factor: 5.449

Review 10.  Classification and definition of disorders causing hypertonia in childhood.

Authors:  Terence D Sanger; Mauricio R Delgado; Deborah Gaebler-Spira; Mark Hallett; Jonathan W Mink
Journal:  Pediatrics       Date:  2003-01       Impact factor: 7.124

View more
  2 in total

Review 1.  Functional Popliteal Artery Entrapment Syndrome: Poorly Understood and Frequently Missed? A Review of Clinical Features, Appropriate Investigations, and Treatment Options.

Authors:  Matthew Hislop; Dominic Kennedy; Brendan Cramp; Sanjay Dhupelia
Journal:  J Sports Med (Hindawi Publ Corp)       Date:  2014-09-07

2.  Architectural changes of the gastrocnemius muscle after botulinum toxin type A injection in children with cerebral palsy.

Authors:  Eun Sook Park; Eungeol Sim; Dong-Wook Rha; Soojin Jung
Journal:  Yonsei Med J       Date:  2014-09       Impact factor: 2.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.